NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will auction off two tickets to the “Big Game” on February 3. Clay Matthews, linebacker of the Green Bay Packers, has donated his game tickets to benefit CureDuchenne. The package includes a four-night hotel stay at the Best Western French Quarter Landmark Hotel in New Orleans. The proceeds will fund research to find a cure for Duchenne. To bid on the tickets, go to charitybuzz.com.
As the most common and lethal form of muscular dystrophy, Duchenne impacts 1 in 3,500 boys. Boys with Duchenne are usually diagnosed before the age of 5, in a wheelchair by age 12 and most don’t survive their mid-20s. There is currently no cure for Duchenne.
Click here to view a public service announcement with Matthews encouraging others to help find a cure for Duchenne. CureDuchenne is the leading organization funding research through venture philanthropy to find a cure.
“Clay has been a big supporter of CureDuchenne, and we appreciate his continued generosity,” said Debra Miller, founder and CEO of CureDuchenne. “We are so close to treatments for Duchenne. Right now the science is not the limitation, it is the funding. We need additional funds to move the research across the goal line in order to cure Duchenne. Bidding on this ticket package will help us raise money to fund more research for Duchenne.”
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.
CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.